Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine in Treating Patients With Myelofibrosis
- Status
- TERMINATED
- Phase
- PHASE2
Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE2
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)
- Status
- COMPLETED
- Phase
- PHASE1
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE1
Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
- Status
- COMPLETED
- Phase
- PHASE3